Rua Bioscience is trading 6.67% down at NZD 0.03 after its rights offer raised about NZ$1.0 million, below the NZ$2.8 million sought.

  • The company said the proceeds do not fully meet its working-capital requirements.
  • The offer added new shares, which may contribute to selling pressure.
  • Available reporting links the shortfall to working-capital needs and does not establish a separate market-wide cause for the decline.